<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083551</url>
  </required_header>
  <id_info>
    <org_study_id>5226</org_study_id>
    <nct_id>NCT00083551</nct_id>
  </id_info>
  <brief_title>UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy</brief_title>
  <official_title>UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to evaluate whether &quot;anti-angiogenesis&quot; therapy with thalidomide
      and whether additional chemotherapy after transplant will be beneficial. Another objective is
      to find out what kinds of side effects occur with this combination of treatment and how often
      they occur.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will be given in 4 phases or steps: Induction, Transplant 1 and 2, Consolidation,
      and maintenance. Induction is designed to induce (or bring about) myeloma into remission.
      Each patient enrolled on this study will be randomly assigned to receive the above treatment
      alone or in combination with a drug called thalidomide. Some patients may be eligible to
      receive the transplant as an outpatient, based on general health and other factors.After
      recovery from the transplant phase of the study (approximately 6 weeks), patients originally
      assigned to thalidomide will resume taking it and will continue taking it throughout the rest
      of the study treatment. All patients will receive post-transplant consolidation treatment,
      which in earlier studies has been found to be helpful in maintaining patients response after
      transplant. Therefore, all patients will receive a combination of drugs called &quot;D PACE&quot; which
      consists of Dexamethasone, Cis-Platinum, Adriamycin, Cyclophosphamide, and Etoposide. If you
      are also taking thalidomide, you will continue taking it throughout, and the treatment is
      called &quot;DT PACE&quot; to include the thalidomide. No sooner than 4 weeks, and no later than 12
      weeks after consolidation and if your myeloma remains in remission after consolidation
      therapy is complete, you will begin the last phase of the study, which is maintenance.
      Maintenance is designed to keep your myeloma in remission long-term.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 Years</time_frame>
    <description>Overall Survival at six years after initiating protocol therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">668</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thalidomide 400 qod during induction.100 mg qd between transplants, post transplant pat. 200 mg qd. During year one of maintenance therapy pt will take 100mg of Thal qod and 50 mg of thal qod during second year of maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Thalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During induction, consolidation, and maintenance steps patient receives no thalidamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).
Start infusion 30 minutes after completion of BCNU on day -5.</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU</intervention_name>
    <description>Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Carmustine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)
*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) &lt; 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) &gt; 3.0 mg/dl</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>cisplatinum</other_name>
    <other_name>cis-diamminedichloroplatinum</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytoxan</intervention_name>
    <description>Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as &lt; 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Tobradex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.</description>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>hydroxydaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Eposin</other_name>
    <other_name>Etopophos</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Grafeel</other_name>
    <other_name>Religrast</other_name>
    <other_name>Nugraf</other_name>
    <other_name>Shilgrast</other_name>
    <other_name>Neukine</other_name>
    <other_name>Emgrast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant GM-CSF</intervention_name>
    <description>GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha-2b</intervention_name>
    <description>AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.</description>
    <arm_group_label>No Thalidomide</arm_group_label>
    <other_name>Oncovin</other_name>
    <other_name>leurocristine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have newly diagnosed active multiple myeloma requiring treatment.
             Patients with a previous history of smoldering myeloma will be eligible if there is
             evidence of progressive disease requiring chemotherapy.

          -  Protein criteria must be present in order to evaluate response.Non-secretory patients
             are eligible provided the patient has &gt; or = 20% plasmacytosis or multiple (&gt;3) focal
             plasmacytomas on MRI or diffuse hyperintense signal on STIR images in the absence of
             hematopoietic growth factors is seen.

          -  All necessary baseline studies for determining stage, bloodwork, and bone marrow must
             be obtained within 35 days prior to registration.

          -  Patients must have received no more than one cycle of prior chemotherapy including one
             month of Dexamethasone and Thalidomide for this disease. Patients may have received
             prior radiotherapy provided approval has been obtained by one of the study
             coordinators.

          -  Patients must have a performance status of 0-2 based on SWOG criteria. Patients with a
             poor performance status (3-4), based solely on bone pain, will be eligible.

          -  Patients with renal failure, even if on dialysis, are eligible if it is felt to be due
             to myeloma and if the duration of renal failure does not exceed two months

          -  Patients must be 75 years of age or less at the time of registration

          -  All patients must be informed of the investigational nature of this study and must
             sign and give written informed consent in accordance with institutional and federal
             guidelines.

          -  If medically appropriate, patients with pathologic fractures, pneumonia at diagnosis
             or hyperviscosity with shortness of breath should have these conditions attended to
             prior to registration.

        Exclusion Criteria:

          -  Patients must not have significant co-morbid medical conditions or uncontrolled life
             threatening infection

          -  Patients must not have uncontrolled diabetes

          -  Patients with recent (&lt; or =6 months) myocardial infarction, unstable angina,
             difficult to control congestive heart failure, uncontrolled hypertension, or difficult
             to control cardiac arrythmias are ineligible. Ejection fraction by ECHO or MUGA should
             be within the institutional normal range and must be performed within 42 days prior to
             registration.

          -  Patients must not have a history of chronic obstructive or chronic restrictive
             pulmonary disease.

          -  No prior malignancy is allowed except for adequately treated basal cell or squamous
             cell skin cancer, in situ cervical cancer, or other cancer for which the patient has
             been disease free for at least three years.Prior malignancy is acceptable provided
             there has been no evidence of disease within the three-year interval and there must be
             no prior treatment with cytotoxic drugs that could potentially be assigned on this
             treatment protocol.

          -  Pregnant or nursing women may not participate. Women of child-bearing potential must
             have a negative pregnancy documented within one week of registration. Women/men of
             reproductive potential may not participate unless they have agreed to use two forms of
             effective contraceptive method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Barlogie, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences/MIRT</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://myeloma.uams.edu</url>
    <description>Myeloma Institute for Research &amp; Therapy website</description>
  </link>
  <results_reference>
    <citation>Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9;354(10):1021-30.</citation>
    <PMID>16525139</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2004</study_first_submitted>
  <study_first_submitted_qc>May 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2004</study_first_posted>
  <results_first_submitted>August 24, 2015</results_first_submitted>
  <results_first_submitted_qc>August 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2015</results_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Cancer</keyword>
  <keyword>Therapy</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>DTPACE</keyword>
  <keyword>Transplant</keyword>
  <keyword>VAD</keyword>
  <keyword>DCEP</keyword>
  <keyword>CAD</keyword>
  <keyword>Consolidation</keyword>
  <keyword>Melphalan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thalidomide</title>
          <description>Thalidomide 400 QD during induction, 100 mg QD between transplants, 200 mg QD post transplant, 100 mg QD during year one of maintenance, and 50 mg QD during second year of maintenance.</description>
        </group>
        <group group_id="P2">
          <title>No Thalidomide</title>
          <description>Patient received no thalidomide during induction, consolidation, and maintenance therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="345"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="345"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thalidomide</title>
          <description>Thalidomide 400 QD during induction, 100 mg QD between transplants, 200 mg QD post transplant, 100 mg QD during year one of maintenance, and 50 mg QD during second year of maintenance.</description>
        </group>
        <group group_id="B2">
          <title>No Thalidomide</title>
          <description>Patient received no thalidomide during induction, consolidation, and maintenance therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="323"/>
            <count group_id="B2" value="345"/>
            <count group_id="B3" value="668"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;/= 60 to &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall Survival at six years after initiating protocol therapy</description>
        <time_frame>6 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide</title>
            <description>Thalidomide 400 QD during induction, 100 mg QD between transplants, 200 mg QD post transplant, 100 mg QD during year one of maintenance, and 50 mg QD during second year of maintenance.</description>
          </group>
          <group group_id="O2">
            <title>No Thalidomide</title>
            <description>Patient received no thalidomide during induction, consolidation, and maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival at six years after initiating protocol therapy</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Thalidomide</title>
          <description>Thalidomide 400 QD during induction, 100 mg QD between transplants, 200 mg QD post transplant, 100 mg QD during year one of maintenance, and 50 mg QD during second year of maintenance.</description>
        </group>
        <group group_id="E2">
          <title>No Thalidomide</title>
          <description>Patient received no thalidomide during induction, consolidation, and maintenance therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="323" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="345" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Clotting-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Prothrombin time increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Anemia (HGB)</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Neutropenia/granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="259" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Platelet transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Thrombocytopenia (PLT)</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Leukopenia (WBC)</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="279" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hemorrhage w/3-4 thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hemorrhage w/3-4 thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hemorrhage w/o 3-4 thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hemorrhage-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Vaginal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Petechiae/purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Melena/GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Melena/GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Arrhythmia, NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Arrhythmia, NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Cardiovascular-other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Cardiovascular-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Conduction abnormality/block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Conduction abnormality/block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Edema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 LVEF decrease/CHF</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Nodal/junctional dysrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Surgery-injury of vein/artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Syncope</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Valvular heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Vasovagal episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Supra Arrhyth: Atrial Fib.</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Cardiac/heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Chest/thorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Hearing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Inner ear - hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Middle ear - hearing loss/otitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Earache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Endocrine - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 SIADH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Cataract</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Double vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Eye - other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Anal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Colitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Constipation/bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Constipation/bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Diarrhea with colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Diarrhea without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Diarrhea without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Esophagitis/dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Esophagitis/dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Mucositis, NOS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 GI Mucositis, NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 GI-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 GI-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Mouth Dryness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Mouth Dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Periodontal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 RT-GI mucositis, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Stomatitis/pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Stomatitis/pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Fatigue/malaise/lethargy</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Fatigue/malaise/lethargy</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Fever without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Fever without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Fever, NOS</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Fever, NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Flu-like symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Sweating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Abdominal pain/cramping</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Abdominal pain/cramping</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Chest pain/not cardio or pleural</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Extremity/limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hip-left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Lower back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Neuropathic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pain/other</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Pain/other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pelvic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Rectal/perirectal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Rib</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Upper Back</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Failure to engraft</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Stem cell infusion complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Stem cell infusion complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Syndrome/other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Bilirnbin increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Liver enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Allergic/hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Autoimmune reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Autoimmune reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Ear infection ANC mid ear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 GI infection 3-4 ANC abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 GI infection 3-4 ANC appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Infection 3-4 ANC tooth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 GI infection ANC abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 GU infection ABC UTI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/grade 3 or 4 Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/o 3-4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Infection w/o 3-4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/3-4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Infection w/3-4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection ANC</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Infection ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung infection 3-4 ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung Infection ANC Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung Infection ANC Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung Infection ANC Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Moderate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Respiratory infect w/neutrop</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Muscle infection ANC Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Respiratory infection w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Respiratory infection w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Respiratory infection ANC</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Skin infection 3-4 ANC lip/perior</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Surgery-wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Surgery -wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Urinary tract infectiob w/neutrop</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Uninary tract infection w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Urinary tract infection w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Urinary tract infection ANC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypermatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Gait/Walking</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Gait/Walking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Joint, muscle, bone</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Myalgia/arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Grade 4 Second primary</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Apnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Anxiety/agitation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Anxiety/agitation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Depression</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Dizziness/light headedness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Dizziness/light headedness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Dizziness/vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Involuntary movement/restlessnes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Mood/consciousness change</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Mood/consciousness change</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Neuro-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Neuro-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Seizures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Sensory/neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Sensory/neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Somnolence/consciousness loss</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Somnolence/consciousness loss</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade4 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Weakness (motor neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Weakness (motor neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Bladder Spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Bladder Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 GU-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Female sterility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Menses changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 4 Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung-other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Lung-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pleural effusions</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pneumonitis/infilitrates</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Pneumonitis/infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Voice charge /stridor/larynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Decubitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Erythema multifrme/blistering</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Erythema/rash/eruption/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Skin/other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="323" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="345" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Anemia (HGB)</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Anemia (HGB)</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Neutropenia/ granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 PRBC transfusion</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Platelet Transfusion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 3 Thrombocytopenia (PLT)</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hemorrhage w/3-4 thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Arrythmia, NOS</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Arrythmia, NOS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Edema</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Edema</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Eye - other</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Vision, NOS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Constipation/bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Constipation/bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Diarrhea without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Diarrhea without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Esophagitis/dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Esophagitis/dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Mouth Dryness</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Mouth Dryness</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Stomatitis/pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Stomatitis/pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Taste Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Fatigue/malaise/lethargy</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Fever without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Fever without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Fever, NOS</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Fever, NOS</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Flu-like symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 sweating</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 sweating</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Edema-limb</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Abdominal pain/cramping</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Pain/other</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Pain/other</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Upper back</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Upper back</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Stem cell infusion complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Autoimmune reaction</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Infection w/Grade 3 or 4 Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Infection w/o 3-4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Lung Infection ANC Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Respiratory infection w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Respiratory infection w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypematremia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Joint, muscle, bone</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Joint, muscle, bone</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Anxiety/agitation</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Anxiety/agitation</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Depression</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Depression</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Dizziness/light headedness</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Dizziness/light headedness</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Headache</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Headache</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Memory loss</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Mood/consciousness change</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Mood/consciousness change</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Sensory/neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Somnolence/consciousness loss</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Somnolence/consciousness loss</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Weakness (motor neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Weakness (motor neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Bladder Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Cough</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Cough</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Pneumonitis/infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Bruising</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Erythema/rash/eruption/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Erythema/rash/eruption/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 1 Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 2 Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grade 4 Skin/other</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bart Barlogie</name_or_title>
      <organization>UAMS Myeloma Institute</organization>
      <phone>501-526-6990 ext 2420</phone>
      <email>barlogiebart@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

